Clopidogrel
Product Images NDC 31722-902

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 31722-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel300mg30s (Clopidogrel300mg30s)

This is a medication called Clopidogrel Tablet, which contains 391.5 mg of Clopidogrel bisulfate, USP equivalent to 300 mg of clopidogrel base. It is meant for adults, and the usual adult dosage is not provided in the text, but can be found in the package insert. The medication should be stored at a temperature between 20-25°C (68-77°F), and up to 30°C (86°F) is permitted. The manufacturer is Camber Pharmaceuticals, Inc. The text also includes some codes and contact information.*

FDA Label Image

Clopidogrel30s75mg (Clopidogrel30s75mg)

The text describes the composition and dosage of Clopidogrel bisulfate tablets, which contains 97.875mg of the active ingredient, equivalent to 75mg of clopidogrel base. The recommended storage temperature range and contact information are provided. The drug is distributed in a package of 30 tablets and comes with a Medication Guide that should be provided to each patient. The manufacturer is Camber Pharmaceuticals, and the drug is produced by ScieGen Pharmaceuticals. The lot and expiration dates are also mentioned.*

FDA Label Image

Clopidogrelfigure2 (Clopidogrelfigure2)

This document appears to be a medical report or record, specifically detailing cases of cardiovascular death, myocardial infarction (heart attack) and stroke. The location mentioned is "Wyocarta" and there is a reference to a "CURE Sty" which may indicate a treatment or intervention program. The document is labeled "PLACESO (1 cpi)".*

FDA Label Image

Clopidogrelfigure6 (Clopidogrelfigure6)

FDA Label Image

Clopidogrelfigure8 (Clopidogrelfigure8)

FDA Label Image

Clopidogrelfigure3 (Clopidogrelfigure3)

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure4 (Figure4)

FDA Label Image

Figure5 (Figure5)

This appears to be a description of a clinical trial comparing the efficacy of a placebo versus a medication called Clopidogrel in reducing the risk of death, re-infarction (the formation of a new blood clot) or stroke before a patient's first discharge. The results show that a smaller percentage of patients taking Clopidogrel experienced an event compared to those taking the placebo, with a 9% proportional risk reduction that was statistically significant (p=0.002). The timeline for the study extended up to 28 days since the start of the trial.*

FDA Label Image

Figure8 (Figure8)

The text describes a chart or a table showing the cumulative event rate (% of fatal or non-fatal vascular events) of Clopidogrel Bisulfate after 22 months of follow-up. There are percentages listed for time periods of 0, 12, 18, and 22 months.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.